FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Input metadata referenced "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Adherex is a biopharmaceutical company focused on cancer therapeutics. The company has no commercial products and has incurred significant operating losses since inception. Its primary focus is the development of eniluracil (in combination with 5-FU) and STS (sodium thiosulfate) to prevent chemotherapy-induced hearing loss. The company terminated its license agreement with McGill University regarding ADH-1 in late 2009.

Key Financial Metrics

Note: The 2010 net loss includes a non-cash unrealized loss of $3.25 million related to the fair value adjustment of derivative warrants issued in a private placement.

Material Changes vs. Prior Period

• Financing Activity: In April 2010, the company completed a non-brokered private placement raising gross proceeds of CAD$7.2 million (approx. $7.19 million USD net cash provided by financing). This significantly increased cash reserves from $0.69 million in 2009 to $5.95 million in 2010.
• Derivative Liability: Due to the issuance of warrants denominated in Canadian dollars (while the functional currency is USD), the company recorded a derivative warrant liability of $10.45 million, resulting in a $3.25 million non-cash loss in 2010. No such liability existed in 2009.
• Expense Shifts: R&D expenses decreased by 66% due to the closure of clinical studies and settlement of prior year amounts. Conversely, G&A expenses increased by 221%, primarily driven by $2.5 million in non-cash stock-based compensation and costs associated with the 2011 Rights Offering.
• Management Changes: Significant restructuring occurred in 2009, with new leadership (CEO, CFO, CSO) appointed in July and September 2009.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The company explicitly states that its operating losses and accumulated deficit raise substantial doubt about its ability to continue as a going concern. It requires additional funding to finance its business strategy and operations.
• Capital Requirements: Management believes current cash is sufficient to satisfy anticipated capital requirements through the fiscal year ended December 31, 2011. However, projections are subject to substantial uncertainty.
• Financing Activities:
  • April 2010 Private Placement: Raised CAD$7.2 million to fund eniluracil Phase II trial design.
  • March 2011 Rights Offering: Commenced March 2, 2011. Preliminary calculations as of March 29, 2011, indicated subscriptions for approximately 85 million units, representing estimated gross proceeds of CAD$2.5 million.
• Development Pipeline:
  • Eniluracil: Protocol submitted to FDA and Russian authorities in Q3 2010. Recruitment for a Phase II trial (approx. 140 patients) was anticipated to open in Q2 2011.
  • STS: Phase III trials are ongoing with SIOPEL and the Children's Oncology Group to prevent hearing loss in pediatric patients receiving cisplatin.
• Internal Controls: Management identified two material weaknesses in internal control over financial reporting: (1) lack of sufficient staff to segregate accounting duties (one full-time employee performing all duties) and (2) insufficient personnel with appropriate technical accounting knowledge for U.S. GAAP.
• Risks: High risk of failure in clinical trials, inability to raise additional capital, intense competition, and reliance on third-party collaborators and manufacturers.

Key Facts for Investor Verification

• Liquidity Status: Verify the final proceeds from the March 2011 Rights Offering (preliminary estimate was CAD$2.5 million) and whether this is sufficient to fund the planned Phase II eniluracil trial through 2011.
• Derivative Liability Impact: Confirm the fair value of the $10.45 million derivative warrant liability and monitor for further non-cash losses if the stock price or exchange rate fluctuates.
• Clinical Trial Progress: Verify the actual start date and patient enrollment rates for the eniluracil Phase II trial, as delays could necessitate immediate additional financing.
• Internal Control Remediation: Assess the company's ability to hire qualified accounting staff to remediate the identified material weaknesses in internal controls.
• Stock Dilution: Note the significant number of outstanding warrants (240 million) and options (83 million) which represent substantial potential dilution to existing shareholders.